immorta bio board appointment
Board Tactics vs Longevity Science: Immorta Bio's Real Move?
Immorta Bio’s hiring of former EY health-sciences partner Howard Brooks marks a clear pivot toward regulatory governance rather than pure scientific talent, aiming to de-risk its anti-aging pipeline. According to a 2025 McKinsey survey, 60% of respondents say healthy aging is a top financial priority, underscoring why investors watch